Popular Articles

House Panel Passes Protection For Drug Makers
The House Energy and Commerce Committee passed an amendment to their broad health reform bill giving drug makers 12 years of exclusive rights to market new biologic drugs, "a setback" to the administration and consumer advocates who hoped to make generic drugs more widely available, the Wall Street Journal reports. The panel voted 47-11 on the measure, which "would also allow "evergreening," the practice by pharmaceutical companies of making minimal adjustments to their drugs, such as creating extended-release versions, as a way to lengthen their monopoly."
drugs without prescription
IFPMA R&D Status Report 2009: Industry Research Increasing In Less Well-known Tropical Diseases
The IFPMA has just published the 2009 edition of its Status Report on Pharmaceutical Industry R&D for Diseases of the Developing World(1). This documents research and development projects by IFPMA member companies(2), alone or with partners, to develop medicines and vaccines for the 10 diseases of the developing world (DDW)(3) prioritized by the United Nations" TDR tropical disease research and training organization(4). Member company DDW medicine and vaccine projects have increased from 67 last year to a total of 84 this year. While the number of tuberculosis and malaria projects has grown slightly, projects for the remaining eight tropical diseases have increased markedly from 11 in 2008 to 25 in 2009.
News of the day
Canada Continues To Work With National And International Partners To Manage The Spread Of The H1N1 Flu Virus
Health Minister Leona Aglukkaq updated Canadians on the H1NI flu virus response and reemphasized the Government of Canada"s ongoing collaboration with its national and international partners to manage the spread of this virus. The Minister and Canada"s Chief Public Health Officer, Dr. David Butler-Jones will be participating in an international meeting on the global response to H1N1 flu virus in Cancun, Mexico from July 1-3.
Oncology

Joint Statement On Atypical Antipsychotic Use In Children

As advocates for people living with mental illnesses, we strongly urge the FDA to carefully consider the importance of viable treatment options for bipolar disorder and schizophrenia in pediatric and adolescent populations. Access to safe and effective treatments, including more information about all treatment options, is crucial to treating these serious and complex conditions in children and adolescents. Bipolar disorder and schizophrenia are very real, life-threatening diseases which can appear in childhood and adolescence. For example, federally funded research (STEP-BD) found that, of 3,658 adult patients studied, 68% reported bipolar disease onset in childhood or adolescence. Patients with child onset had, on average, fewer days of euthymia (or neutral mood), greater impairment in functioning and poorer quality of life. Those with adolescent onset have better outcomes than those with child onset, but were still worse off than those who did not suffer from bipolar disorder until adulthood. These alarming statistics highlight the need for early recognition and treatment, which offers children and adolescents their best chance to achieve and maintain wellness. We encourage an open and transparent scientific discourse about all pharmacologic treatments that come before the Advisory Committee and urge the Committee to carefully weigh the available evidence regarding safety and efficacy. No one treatment option works for all children. In order for physicians and families to make informed treatment decisions they need access to a full range of medications and treatment options and to the research regarding the risks and benefits of these treatments. More long-term clinical research in children and adolescents is also needed to better understand the risks and benefits of these medications when used over an extended period. As we know, these medications can also have serious side effects, which is why it is crucial that parents and physicians have as much information as possible in order to make informed decisions and weigh the risk of side effects and adverse reactions against the risk of not treating these very serious diseases. Other treatments for grave childhood illnesses such as cancer can cause hair loss, nausea, compromised immune systems and even death. However, few people question the necessity of these aggressive forms of treatment. Like cancer, aggressive treatment may be needed for some patients with bipolar disorder and schizophrenia, diseases with a higher risk of death than some forms of cancer. The best way to protect the health of our nation"s children and adolescents is to increase access to treatment options and communicate accurate, scientific information that helps parents and physicians cope with and properly treat these devastating illnesses. Our non-profit national mental health advocacy and medical professional organizations represent consumers, physicians, researchers and the top experts in the field of mental health and neuroscience. Mental Health America


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):